SOURCE: IQ Micro Inc.

June 08, 2007 09:45 ET

IQ Micro to Present at Health Sciences Nordic Investment Event at Boston Scientific Corporation

WEST PALM BEACH, FL--(Marketwire - June 8, 2007) - IQ Micro Inc. (OTCBB: IQMC), exclusive licensor of electro-osmotic membranes and micro-pumps for the rapidly emerging microfluidic technology sector, announced today that it will participate in the Health Sciences Nordic Investment Event, to be held at Boston Scientific Corporation in Natick, Mass. on June 12, 2007.

The one-day investment and partnering event, hosted by Innovation Norway, brings together approximately 25 biopharma, medical technology and device companies from Denmark, Finland, Norway and Sweden with interested investors and industry experts. IQ Micro COO Per Arne Lislien and CFO Robert Rudman will participate throughout the day's one-to-one company/investor meetings and present on IQ Micro and its parent company Osmolife's latest developments in the high-growth microfluidics field.

IQ Micro COO Per Arne Lislien said, "As Osmolife continues to pursue innovative applications throughout the health and medical sciences sector -- particularly in the field of glucose monitoring for diabetes -- we are pleased to join this active community of industry leaders in medical technologies and devices. We look forward to presenting at this year's North American Health Sciences Nordic Investment Event held at Boston Scientific Corporation, a well-respected worldwide developer, manufacturer and marketer of medical devices."

IQ Micro is attending the Health Sciences Nordic Investment Event as part of its previously announced collaboration with Innovation Norway, a state-owned company that advances the development and commercialization of new technologies to American and international markets.

About the Health Sciences Nordic Investment Event

The Health Sciences Nordic Investment Event is organized by Invest in Denmark, Finpro, Innovation Norway and Invest in Sweden Agency. Leading North American health science investors and corporations will meet biopharma, medical technology and device companies from the Nordic region at this one-day investment and partnering event. The objective of the Nordic Investment Event is to enable leading VCs and corporate investors to meet key stakeholders and CEOs of Nordic biopharma, medical technology and device companies seeking financing, joint ventures and partnerships.

The Health Sciences Nordic Investment Event will bring together approximately 25 companies from Denmark, Finland, Norway and Sweden, and is hosted by Innovation Norway.

About IQ Micro

IQ Micro Inc. (www.iq-micro.com) is an international licensing company that commercializes proprietary technology developed for use in the microfluidics sector. Developed from the micro-chip industry, microfluidics involves circuits of tiny chambers, channels and pumps that direct the flow of liquids on a single micro-chip.

The company is actively pursuing global licensing opportunities for its patented electro-osmotic membrane technology and its "invisible pump," a microfluidic technology with a wide range of consumer, medical and industrial applications. With its proprietary technology and highly experienced management, IQ Micro expects to become a leading global, specialized supplier of low-voltage microfluidic technology.

IQ Micro's recent Osmotex/Lifecare (Osmolife) parent company merger is expected to result in an expanded licensing arrangement with IQ Micro, which will include exclusive sales and marketing rights to Lifecare's implantable, osmotic sensor for use in diabetes monitoring.

For more information, visit: http://www.iq-micro.com. An investment profile about IQ Micro may be found at http://www.hawkassociates.com/iqmcprofile.aspx. To receive free e-mail notification of future releases for this company, sign up at http://www.hawkassociates.com/email.aspx.

For investor relations information contact D.P. Martin & Associates, Investor Relations for IQ Micro at: (561) 514-0194 or info@dpmartin.com, or visit: www.dpmartin.com.

This release contains various forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, which represent the company's expectations or beliefs concerning future events of the company's financial performance. These forward-looking statements are further qualified by important factors that could cause actual results to differ materially from those in the forward-looking statements. The words "may," "could," "should," "believe," "anticipate," "estimate," "expect," "intend," "plan" and similar words are intended to identify forward-looking statements. These factors include the effect of competitive pricing, the company's dependence on the ability of third-party manufacturers to produce components on a basis which is cost-effective to the company, our ability to protect our intellectual property rights from infringement by third parties, our ability to convert our intellectual property rights into product offerings that are accepted by the market, the development of competitors of intellectual property and associated products that are superior to ours or that gain better market acceptance than ours and the ability of our intellectual property rights to keep pace with the advances in technology, market acceptance of the company's products and licensing rights, the effects of government regulation and other factors. Results actually achieved may differ materially from expected results included in these statements. The company is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise. Furthermore, this company cautions that the risk factors listed in this paragraph are not exhaustive.

Contact Information